Identification of target candidate in Polycystic ovarian syndrome and in vitro evaluation of therapeutic activity of the designed RNA Aptamer

Abstract

Prevalence of poly cystic ovary syndrome has been gradually increasing among adult females and Laparoscopy drilling on the ovary is only available temporary solution with high incidence of reoccurrence. Confidential gene disease association studies combined with various graph theory analysis on the biological protein interaction network of this syndrome has resulted, the 15 genes are overexpressed as central nodes among 434 proteins of disease specific proteome network. Through the Intensive Structural and functional prioritization analysis we have identified S100A8, calprotectin is the ideal drug target protein. In this research, we have constructed RNA library of consensus DNA sequence of Glucocorticoid Response Element (GRE) and screened the best RNA Aptamer fragment which competitively binds with minimal energy to inhibit the cell migration activity of S100A8. In order to prove this computational research, Lipofectamine mediated RNA aptamer delivered and Wound scrap assay in cell lines confirms that the synthesized 18mer oligo has significant molecular level inhibition activity toward cyst formation and spreading in poly cystic condition in ovary.